Andreas Argyrides
Stock Analyst at Oppenheimer
(4.37)
# 356
Out of 5,182 analysts
124
Total ratings
52.78%
Success rate
18.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Outperform | $10 | $5.34 | +87.27% | 1 | Mar 16, 2026 | |
| LQDA Liquidia | Maintains: Underperform | $16 → $19 | $36.25 | -47.59% | 8 | Mar 12, 2026 | |
| GOSS Gossamer Bio | Maintains: Outperform | $12 → $3 | $0.38 | +694.91% | 9 | Mar 5, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $573.46 | +4.63% | 2 | Feb 26, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $30 → $35 | $17.22 | +103.25% | 15 | Feb 24, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $28.07 | +49.63% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $19.21 | +108.22% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.28 | +70.45% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $11.31 | +138.73% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $52.71 | +118.17% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $21 | $4.57 | +359.52% | 2 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $29 | $13.18 | +120.03% | 2 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $33 | $0.19 | +17,728.20% | 2 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $2.70 | +455.56% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.38 | +271.75% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $32.14 | +89.79% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $4.34 | +61.29% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.73 | +73.41% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $0.95 | +322.03% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $13.49 | +567.16% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.74 | +418.73% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $240.29 | -24.67% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $7.84 | +142.35% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $27.38 | +5.92% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.11 | +130.52% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $20.68 | +983.17% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $24.64 | +131.33% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.90 | +677.00% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.26 | +3,783.50% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $54.62 | +28.16% | 6 | Aug 1, 2023 |
Opus Genetics
Mar 16, 2026
Initiates: Outperform
Price Target: $10
Current: $5.34
Upside: +87.27%
Liquidia
Mar 12, 2026
Maintains: Underperform
Price Target: $16 → $19
Current: $36.25
Upside: -47.59%
Gossamer Bio
Mar 5, 2026
Maintains: Outperform
Price Target: $12 → $3
Current: $0.38
Upside: +694.91%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $575 → $600
Current: $573.46
Upside: +4.63%
MoonLake Immunotherapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $30 → $35
Current: $17.22
Upside: +103.25%
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $28.07
Upside: +49.63%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $19.21
Upside: +108.22%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.28
Upside: +70.45%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $11.31
Upside: +138.73%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $52.71
Upside: +118.17%
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $4.57
Upside: +359.52%
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $13.18
Upside: +120.03%
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.19
Upside: +17,728.20%
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $2.70
Upside: +455.56%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.38
Upside: +271.75%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $32.14
Upside: +89.79%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $4.34
Upside: +61.29%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.73
Upside: +73.41%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.95
Upside: +322.03%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $13.49
Upside: +567.16%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.74
Upside: +418.73%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $240.29
Upside: -24.67%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $7.84
Upside: +142.35%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $27.38
Upside: +5.92%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.11
Upside: +130.52%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $20.68
Upside: +983.17%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $24.64
Upside: +131.33%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.90
Upside: +677.00%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.26
Upside: +3,783.50%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $54.62
Upside: +28.16%